Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich Lifesciences Inc (GLSI) is a clinical-stage biopharmaceutical company pioneering immunotherapy solutions to prevent cancer recurrence. This page serves as the definitive source for verified news about GP2 clinical trials, research partnerships, and therapeutic developments in targeted oncology treatments.
Access real-time updates on the company’s immunoadjuvant technologies and HER2/neu-targeted therapies. Investors and researchers will find essential information about clinical milestones, regulatory filings, and scientific publications – all critical for evaluating the company’s position in cancer immunotherapy innovation.
Our curated collection includes earnings reports, trial phase announcements, and strategic collaboration updates. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining scientific accuracy regarding peptide-based immunotherapies and immune response modulation.
Bookmark this page for streamlined access to GLSI’s latest developments in breast cancer immunotherapy and related oncology research. For comprehensive tracking of the company’s progress through clinical development stages, check back regularly for authoritative updates.
Greenwich LifeSciences (NASDAQ: GLSI) provided a year-end update on its clinical-stage immunotherapy, GLSI-100, aimed at preventing breast cancer recurrences. The company is expanding the Flamingo-01 Phase III trial, currently involving 20 US clinical sites recruiting patients, with plans to add 60-75 sites in Europe. CEO Snehal Patel expressed optimism from meetings at the 2022 SABCS and announced commercial manufacturing efforts for GP2, aiming to produce approximately 200,000 doses. A new patent application was filed regarding GP2’s use in immune response assays, enhancing the company's intellectual property portfolio.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced an extension to the lock-up period for shares owned by directors, officers, and pre-IPO investors until December 31, 2023, approximately 39 months post-IPO. The company is focused on developing GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences in patients post-surgery. The ongoing Phase III clinical trial, Flamingo-01, will evaluate the safety and efficacy of GLSI-100 in HER2/neu positive breast cancer patients. The trial aims to detect a hazard ratio of 0.3 in invasive breast cancer-free survival.
Greenwich LifeSciences (GLSI) announced the launch of its Phase III clinical trial, Flamingo-01, aimed at evaluating the immunotherapy GLSI-100 for HER2/neu positive breast cancer patients. The trial, which commenced screening and enrollment at multiple sites, follows promising Phase IIb results showing 100% disease-free survival. The Company is entering pre-commercialization activities, including preparing for a BLA submission and initiating large-scale manufacturing. Key milestones include future presentations of trial data and ongoing licensing discussions.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has initiated the Flamingo-01 Phase III clinical trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences post-surgery. Clinical site activation is in progress across multiple hospitals, alongside site initiation training for clinical staff. The trial intends to enroll approximately 500 patients, with initial Phase III data expected by year-end. The company maintains a strong cash position, allowing for strategic financial maneuvers. CEO Snehal Patel indicated that results from the trial could validate prior Phase IIb findings, which showed no recurrences in treated patients over 5 years.
FAQ
What is the current stock price of Greenwich Lifesciences (GLSI)?
What is the market cap of Greenwich Lifesciences (GLSI)?
